Thyroid medicine recalled nationwide: FDA

Federal regulators have announced a nationwide recall of Levothyroxine Sodium Tablets. This medication is primarily used to treat hypothyroidism and goiter. The FDA issued this recall after reports indicated that the tablets are subpotent. This means the medicine is not fully effective for the conditions it is intended to treat.

The recall process began on July 13 and is classified as a Class II event. This classification indicates that while the use of these tablets may cause temporary adverse health consequences, the situation is being managed closely to prevent further patient impact. The medication was distributed across the United States by Major Pharmaceuticals and Cardinal Health.

Consumers should be aware that the affected products include tablets in various dosages ranging from 25 to 150 micrograms. The specific lots subject to the recall have expiration dates extending from July 2026 through January 2027. These tablets were typically sold in 10-count blister packs, which were available either as individual units or in cartons containing 10 packs.

Patients taking this medication should check their own supply against the details released by the FDA. If you possess these tablets, contact your pharmacist or healthcare provider to discuss the next steps for obtaining safe and effective alternatives. Do not stop your treatment without first consulting a professional, as managing thyroid conditions often requires a consistent dosage plan.

Regulators have not provided the exact number of tablets involved in this recall, but the nationwide scope suggests a wide distribution. Keep an eye on official communication from the FDA or your local pharmacy for further updates regarding this situation. Maintaining awareness of medication safety alerts is a standard part of patient health care.